The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.
Jordan Kharofa
No relevant relationships to disclose
Tracy R. Kelly
No relevant relationships to disclose
Paul S. Ritch
No relevant relationships to disclose
Ben George
No relevant relationships to disclose
Lauren Allison Wiebe
No relevant relationships to disclose
James P. Thomas
No relevant relationships to disclose
Kathleen K. Christians
No relevant relationships to disclose
Douglas B. Evans
No relevant relationships to disclose
Beth Erickson
No relevant relationships to disclose